Published in Schizophr Res on July 17, 2009
Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim Biophys Acta (2011) 1.29
A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology (2010) 1.21
White matter integrity as a predictor of response to treatment in first episode psychosis. Brain (2013) 1.16
Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study. Schizophr Res Treatment (2011) 1.06
Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res (2012) 1.01
Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology (2012) 1.00
Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res (2011) 0.99
Cigarette smoking and white matter microstructure. Psychopharmacology (Berl) (2012) 0.99
White matter changes associated with antipsychotic treatment in first-episode psychosis. Neuropsychopharmacology (2013) 0.99
Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clin Psychopharmacol Neurosci (2012) 0.94
Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology (2012) 0.88
Diffusion tensor imaging, structural connectivity, and schizophrenia. Schizophr Res Treatment (2011) 0.88
Amygdala reactivity in healthy adults is correlated with prefrontal cortical thickness. J Neurosci (2010) 0.88
The early longitudinal course of cognitive deficits in schizophrenia. J Clin Psychiatry (2014) 0.87
White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis. Schizophr Res (2014) 0.85
Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. Neuroimage Clin (2015) 0.84
Auditory verbal hallucinations and the interhemispheric auditory pathway in chronic schizophrenia. World J Biol Psychiatry (2014) 0.83
Long term antipsychotic treatment does not alter metabolite concentrations in rat striatum: an in vivo magnetic resonance spectroscopy study. Schizophr Res (2011) 0.80
Altered human brain anatomy in chronic smokers: a review of magnetic resonance imaging studies. Neurol Sci (2015) 0.80
Assessing intracortical myelin in the living human brain using myelinated cortical thickness. Front Neurosci (2015) 0.79
Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade. J Psychiatry Neurosci (2016) 0.78
Altered intracortical myelin staining in the dorsolateral prefrontal cortex in severe mental illness. Eur Arch Psychiatry Clin Neurosci (2016) 0.78
ADHD comorbidity can matter when assessing cortical thickness abnormalities in patients with bipolar disorder. Bipolar Disord (2012) 0.76
Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls. Schizophr Bull (2015) 0.75
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging (2004) 7.83
Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A (2001) 6.68
Axonal neuregulin-1 regulates myelin sheath thickness. Science (2004) 6.09
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
Age-related alterations in white matter microstructure measured by diffusion tensor imaging. Neurobiol Aging (2004) 4.38
The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry (1999) 4.26
Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry (2005) 3.78
Effects of age on volumes of cortex, white matter and subcortical structures. Neurobiol Aging (2005) 3.63
Normal neuroanatomical variation due to age: the major lobes and a parcellation of the temporal region. Neurobiol Aging (2005) 3.36
Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry (1995) 3.21
Myelination of a key relay zone in the hippocampal formation occurs in the human brain during childhood, adolescence, and adulthood. Arch Gen Psychiatry (1994) 3.18
Age-related total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis. AJNR Am J Neuroradiol (2002) 2.94
Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc Natl Acad Sci U S A (2004) 2.94
Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry (2001) 2.91
Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet (2002) 2.64
Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res (2004) 2.54
Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry (2005) 2.41
Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry (2003) 2.39
Lipid composition of the normal human brain: gray matter, white matter, and myelin. J Lipid Res (1965) 2.35
High cholesterol level is essential for myelin membrane growth. Nat Neurosci (2005) 2.34
Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex (2002) 2.31
Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci U S A (2007) 2.29
Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging (2004) 2.23
Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress. Schizophr Bull (1992) 2.08
Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation. Neuropsychopharmacology (2002) 2.07
White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol (2003) 1.93
Association of genetic risks for schizophrenia and bipolar disorder with specific and generic brain structural endophenotypes. Arch Gen Psychiatry (2004) 1.87
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry (2003) 1.79
Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry (2008) 1.78
Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry (2004) 1.77
Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res (2004) 1.75
Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry (2003) 1.69
Variation with age in the volumes of grey and white matter in the cerebral hemispheres of man: measurements with an image analyser. Neuropathol Appl Neurobiol (1980) 1.67
Changes in volume with age--consistency and interpretation of observed effects. Neurobiol Aging (2005) 1.58
Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry (2007) 1.57
White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci (2007) 1.54
Cholesterol of myelin is the determinant of gray-white contrast in MRI of brain. Magn Reson Med (1991) 1.46
Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res (2008) 1.46
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res (2005) 1.40
Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry (2004) 1.39
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res (2008) 1.37
Volumetric white matter abnormalities in first-episode schizophrenia: a longitudinal, tensor-based morphometry study. Am J Psychiatry (2007) 1.33
Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry (2004) 1.32
Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr Bull (2005) 1.30
Reliability of in vivo volume measures of hippocampus and other brain structures using MRI. Magn Reson Imaging (1993) 1.27
Ultrastructural evidence for diffuse transmission by monoamine and acetylcholine neurons of the central nervous system. Prog Brain Res (2000) 1.27
Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry (1999) 1.26
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J (2005) 1.23
Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur J Neurosci (2004) 1.21
Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cereb Cortex (2008) 1.20
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry (2008) 1.19
Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. Arch Gen Psychiatry (2003) 1.19
MR imaging of the various stages of normal myelination during the first year of life. Neuroradiology (1990) 1.18
Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry (2007) 1.17
Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res (2007) 1.16
Electroconvulsive seizure treatment increases cell proliferation in rat frontal cortex. Neuropsychopharmacology (2005) 1.14
Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry (2003) 1.12
Relational features of acetylcholine, noradrenaline, serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus (1995) 1.10
Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr Res (2005) 1.09
White matter volume changes in people who develop psychosis. Br J Psychiatry (2008) 1.09
Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry (2005) 1.09
The vulnerability/stress model of schizophrenic relapse: a longitudinal study. Acta Psychiatr Scand Suppl (1994) 1.09
Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology (2004) 1.07
Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol (2007) 1.06
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) (2003) 1.06
White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophr Res (2008) 1.04
Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia. Arch Gen Psychiatry (2004) 1.04
Convergent evidence for 2',3'-cyclic nucleotide 3'-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry (2006) 1.04
Targeting synapses and myelin in the prevention of schizophrenia. Schizophr Res (2005) 1.01
Morphometric brain abnormalities in schizophrenia in a population-based sample: relationship to duration of illness. Schizophr Bull (2008) 0.99
SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem (2006) 0.99
Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Mol Psychiatry (2008) 0.99
Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr Res (2005) 0.98
Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder. Neurochem Res (2004) 0.98
Formation, maturation, and disorders of white matter. AJNR Am J Neuroradiol (1992) 0.96
White matter and cognitive function in schizophrenia. Int J Neuropsychopharmacol (2007) 0.96
Postnatal development of the cholinergic innervation in the dorsal hippocampus of rat: Quantitative light and electron microscopic immunocytochemical study. J Comp Neurol (2005) 0.95
Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry (2005) 0.94
Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophr Res (2007) 0.94
Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol Psychiatry (2008) 0.92
Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis. Br J Psychiatry Suppl (2007) 0.90
Reduced intracortical myelination in schizophrenia. Am J Psychiatry (2005) 0.90
Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2004) 0.89
Acetylcholinesterase inhibitors may improve myelin integrity. Biol Psychiatry (2006) 0.88
Lipids in the nervous system of different species as a function of age: brain, spinal cord, peripheral nerve, purified whole cell preparations, and subcellular particulates: regulatory mechanisms and membrane structure. Adv Lipid Res (1972) 0.88
An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther (2008) 0.87
Linkage evidence of schizophrenia to loci near neuregulin 1 gene on chromosome 8p21 in Taiwanese families. Am J Med Genet B Neuropsychiatr Genet (2005) 0.87
Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2004) 0.86
BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION. Adolesc Psychiatry (2005) 0.86
Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation. Glia (2005) 0.85
Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm (Vienna) (2006) 0.84
Neurotransmitter-mediated regulation of CNS myelination: a review. Acta Neurol Belg (1999) 0.84
Adjunctive treatment of acute mania: a clinical overview. Acta Psychiatr Scand Suppl (2007) 0.83
Total length of nerve fibers in prefrontal and global white matter of chronic schizophrenics. J Psychiatr Res (2003) 0.83
ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) (2005) 0.82
Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J (2007) 0.82
Frontal and temporal volume size of grey and white matter in patients with schizophrenia: an MRI parcellation study. Eur Arch Psychiatry Clin Neurosci (2007) 0.82
Temporal lobe volume in bipolar disorder: relationship with diagnosis and antipsychotic medication use. J Affect Disord (2008) 0.81
Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA (2006) 6.48
Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry (2006) 5.30
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull (2005) 4.66
Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry (2004) 4.46
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry (2008) 4.02
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am J Psychiatry (2008) 3.29
Distinguishing random environmental fluctuations from ecological catastrophes for the North Pacific Ocean. Nature (2005) 3.04
Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry (2007) 2.91
Brief cognitive-behavioral therapy effects on post-treatment suicide attempts in a military sample: results of a randomized clinical trial with 2-year follow-up. Am J Psychiatry (2015) 2.80
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull (2006) 2.53
Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry (2011) 2.47
Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry (2007) 2.47
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry (2007) 2.45
Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia. Am J Psychiatry (2006) 2.42
Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry (2006) 2.29
The poor prognosis of childhood-onset bipolar disorder. J Pediatr (2007) 2.26
Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease. Neurobiol Aging (2004) 2.23
Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol (2003) 2.20
Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry (2008) 2.17
Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res (2009) 2.08
Consistency of Brief Psychiatric Rating Scale factor structure across a broad spectrum of schizophrenia patients. Psychopathology (2007) 2.01
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol (2003) 1.93
Evidence for deficient modulation of amygdala response by prefrontal cortex in bipolar mania. Psychiatry Res (2007) 1.93
Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2011) 1.93
Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry (2002) 1.93
Lifespan trajectory of myelin integrity and maximum motor speed. Neurobiol Aging (2008) 1.92
Diffusion tensor imaging of the superior longitudinal fasciculus and working memory in recent-onset schizophrenia. Biol Psychiatry (2007) 1.89
Is emotion processing a predictor of functional outcome in schizophrenia? Schizophr Bull (2003) 1.89
The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull (2006) 1.88
Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging (2006) 1.87
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
Increased amygdala activation during mania: a functional magnetic resonance imaging study. Am J Psychiatry (2005) 1.84
Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord (2009) 1.82
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Social cognition in schizophrenia, Part 1: performance across phase of illness. Schizophr Bull (2011) 1.77
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry (2004) 1.72
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia. Schizophr Bull (2007) 1.72
Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72
Does anhedonia in schizophrenia reflect faulty memory for subjectively experienced emotions? J Abnorm Psychol (2006) 1.71
Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment. Psychiatr Rehabil J (2008) 1.70
Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord (2011) 1.67
Neurocognitive performance and functional disability in the psychosis prodrome. Schizophr Res (2006) 1.67
A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am J Psychiatry (2003) 1.63
Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. Neurochem Res (2007) 1.63
Schizophrenia as one extreme of a sexually selected fitness indicator. Schizophr Res (2004) 1.61
Regional fMRI hypoactivation and altered functional connectivity during emotion processing in nonmedicated depressed patients with bipolar II disorder. Am J Psychiatry (2012) 1.61
Placental passage of antidepressant medications. Am J Psychiatry (2003) 1.61
Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry (2010) 1.60
The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res (2004) 1.59
Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch Gen Psychiatry (2005) 1.57
The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry (2005) 1.56
Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr Bull (2011) 1.56
A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry (2002) 1.55
Schizophrenia patients demonstrate a distinctive pattern of decision-making impairment on the Iowa Gambling Task. Schizophr Res (2005) 1.54
Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol (2007) 1.54
The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord (2012) 1.54
Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry (2010) 1.51
High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry (2002) 1.48
Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord (2007) 1.46
Elucidating a magnetic resonance imaging-based neuroanatomic biomarker for psychosis: classification analysis using probabilistic brain atlas and machine learning algorithms. Biol Psychiatry (2009) 1.45
Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry (2005) 1.44
Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord (2003) 1.44
Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry (2003) 1.44
Blunted activation in orbitofrontal cortex during mania: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 1.44
The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res (2010) 1.43
Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull (2011) 1.38
Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 1.35
Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression. Neuropsychopharmacology (2007) 1.33
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry (2007) 1.32
Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry (2013) 1.30
Neuropsychological deficits among patients with late-onset minor and major depression. Arch Clin Neuropsychol (2003) 1.30
Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res (2008) 1.29
A videotape intervention to enhance the informed consent process for medical and psychiatric treatment research. Am J Psychiatry (2005) 1.29
Computer-assisted self-assessment in persons with severe mental illness. J Clin Psychiatry (2004) 1.28
Do the siblings of schizophrenia patients demonstrate affect perception deficits? Schizophr Res (2004) 1.27
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. Neuropsychopharmacology (2006) 1.27
Executive functioning component mechanisms and schizophrenia. Biol Psychiatry (2008) 1.27
Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine. J Affect Disord (2007) 1.26